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Nonalcoholic fatty liver disease is one of the most com-
mon causes of chronic liver disease in the United States. It
is estimated that 3% of US population has nonalcoholic
steatohepatitis (NASH). NASH can progress to cirrhosis
leading to development of hepatocellular carcinoma.
Previously, we have demonstrated that hepatic stellate
cells (HSC) in sinusoidal lesions of liver in patients with
NASH express high levels of high-affinity Interleukin-13R
alpha2 (IL-13Ra2), which is co-localized with smooth
muscle actin. In contrast, fatty liver and normal liver speci-
mens do not express IL-13Ra2. To simulate human hepa-
tic fibrotic disease, we also developed NASH in rats by
feeding a choline-deficient L-amino acid diet. These rats
developed liver fibrosis and increased liver enzymes in the
periphery [1]. Here we report generation of another model
of NASH by feeding a choline-deficient (CDAA) diet to
mice. CDAA fed mice developed significant liver fibrosis
as evident by hydroxyproline assay and collagen-1 mRNA
expression. Interestingly, these mice also developed
macroscopic liver tumors in a long term follow-up study.
Existence of tumors was confirmed histologically. CDAA
mouse livers overexpressed IL-13Ra2 chain at mRNA and
protein levels but decreased serum albumin, increased
alkaline phosphatase and alanine aminotransferase but
total bilirubin values were unaffected. When these mice
were treated with low doses of IL-13PE immunotoxin, we
did not observe any decrease in fibrosis. However, they
showed improved serum albumin and alkaline phospha-
tase levels, but had no effect on alanine aminotransferase
and total bilirubin. When CDAA mice were treated with
higher dose of IL13-PE (100 µg/kg/day), a significant
decrease in fibrosis was observed. CDAA diet significantly
increased TGF-b1 levels in the liver, which was also
reversed by high dose IL-13PE treatment. Further IHC
analyses in mouse liver specimens revealed that CDAA
diet activated the hepatic stellate cells and increased TGF-
b1 and IL-13Ra2 expression. IL-13PE decreased both
TGF-b1 and IL-13Ra2 expression, but did not affect acti-
vation of the hepatic stellate cells. Additional studies are
ongoing to examine the effect of IL-13-PE on liver tumor
development. These results indicate that IL-13Ra2 tar-
geted immunotherapeutic approaches either alone or in
combination with other therapeutic agents may provide
viable options for therapy of NASH and prevention of
development of hepatocellular carcinoma.
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